drugset / Trial / NCT00996385

Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma

NCT00996385 ↗

Phase 2 Unknown 29 enrolled Columbia University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study chemotherapy will consist of four treatments with Velcade (days 1, 4, 15, and 18) and two treatments with Eloxatin(days 4 and 18). Patients will be undergo standard of care blood work and Quality of Life (QOL) questionnaires at each visit and will be have repeat CT scans performed to assess tumor response every 2 cycles (8 weeks). Each patient will be allowed to receive a maximum of 6 cycles of therapy. Following discontinuation of treatment due to disease progression or completion of therapy, patient's will be followed for survival, QOL assessments, and tumor assessments every 3 months (or as clinically indicated) for the first year and every 3 months thereafter for a maximum of 5 years.

Timeline

Start
2009-09
Primary completion
2013-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 —
Subject Oxaliplatin Small molecule 85 mg/m2 —

Indications